as of 12-08-2025 3:42pm EST
MAIA Biotechnology Inc is a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer. THIO (6-thio-dG or 6-thio-2 '-deoxyguanosine), its lead asset, is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. Patients with advanced NSCLC will be treated first with THIO followed a few days later by the immune checkpoint inhibitor Libtayo (cemiplimab), manufactured and commercialized by Regeneron.
| Founded: | 2018 | Country: | United States |
| Employees: | N/A | City: | CHICAGO |
| Market Cap: | 44.9M | IPO Year: | 2022 |
| Target Price: | N/A | AVG Volume (30 days): | 449.7K |
| Analyst Decision: | N/A | Number of Analysts: | N/A |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.77 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.87 - $2.74 | Next Earning Date: | 11-07-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Machine learning model trained on 25+ technical indicators
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Director
Avg Cost/Share
$1.11
Shares
18,145
Total Value
$20,229.86
Owned After
437,628
SEC Form 4
Chief Executive Officer
Avg Cost/Share
$1.14
Shares
50,000
Total Value
$56,830.00
Owned After
881,421
SEC Form 4
Director
Avg Cost/Share
$1.08
Shares
20,000
Total Value
$21,616.00
Owned After
437,628
SEC Form 4
Director
Avg Cost/Share
$1.04
Shares
15,000
Total Value
$15,582.00
Owned After
1,364,289
SEC Form 4
Chief Executive Officer
Avg Cost/Share
$1.05
Shares
22,000
Total Value
$23,018.60
Owned After
881,421
SEC Form 4
Director
Avg Cost/Share
$0.98
Shares
10,000
Total Value
$9,785.00
Owned After
437,628
SEC Form 4
Director
Avg Cost/Share
$0.98
Shares
15,000
Total Value
$14,700.00
Owned After
1,364,289
SEC Form 4
Chief Executive Officer
Avg Cost/Share
$0.97
Shares
10,500
Total Value
$10,144.05
Owned After
881,421
SEC Form 4
Director
Avg Cost/Share
$0.99
Shares
10,000
Total Value
$9,900.00
Owned After
1,364,289
SEC Form 4
Chief Executive Officer
Avg Cost/Share
$0.99
Shares
10,000
Total Value
$9,891.00
Owned After
881,421
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Luput Cristian | MAIA | Director | Nov 28, 2025 | Buy | $1.11 | 18,145 | $20,229.86 | 437,628 | |
| Vitoc Vlad | MAIA | Chief Executive Officer | Nov 28, 2025 | Buy | $1.14 | 50,000 | $56,830.00 | 881,421 | |
| Luput Cristian | MAIA | Director | Nov 26, 2025 | Buy | $1.08 | 20,000 | $21,616.00 | 437,628 | |
| Smith Stan | MAIA | Director | Nov 26, 2025 | Buy | $1.04 | 15,000 | $15,582.00 | 1,364,289 | |
| Vitoc Vlad | MAIA | Chief Executive Officer | Nov 26, 2025 | Buy | $1.05 | 22,000 | $23,018.60 | 881,421 | |
| Luput Cristian | MAIA | Director | Nov 25, 2025 | Buy | $0.98 | 10,000 | $9,785.00 | 437,628 | |
| Smith Stan | MAIA | Director | Nov 25, 2025 | Buy | $0.98 | 15,000 | $14,700.00 | 1,364,289 | |
| Vitoc Vlad | MAIA | Chief Executive Officer | Nov 25, 2025 | Buy | $0.97 | 10,500 | $10,144.05 | 881,421 | |
| Smith Stan | MAIA | Director | Nov 24, 2025 | Buy | $0.99 | 10,000 | $9,900.00 | 1,364,289 | |
| Vitoc Vlad | MAIA | Chief Executive Officer | Nov 24, 2025 | Buy | $0.99 | 10,000 | $9,891.00 | 881,421 |
MAIA Breaking Stock News: Dive into MAIA Ticker-Specific Updates for Smart Investing
See how MAIA stacks up against similar companies in the market
Enhance your trading experience with our free tools
The information presented on this page, "MAIA MAIA Biotechnology Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.